ATAI Life Sciences NV Market Cap ($1.27 Billion)
Market Cap & Net Worth: ATAI Life Sciences NV (9VC)
ATAI Life Sciences NV market cap. ATAI Life Sciences NV (XETRA:9VC) has a market capitalization of $1.27 Billion (€1.09 Billion) as of November 2, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #7588 globally and #1051 in its home market, demonstrating a -2.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ATAI Life Sciences NV's stock price €3.43 by its total outstanding shares 363214602 (363.21 Million). Also see ATAI Life Sciences NV (9VC) cash conversion ratio for how efficiently the company converts equity into cash flow.
ATAI Life Sciences NV Market Cap History (2021–2025)
ATAI Life Sciences NV market cap history from 2021 to 2025. Data shows change from $2.75 Billion to $1.45 Billion (-24.16% CAGR). Check ATAI Life Sciences NV stock price for real-time trading data and today's change.
ATAI Life Sciences NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ATAI Life Sciences NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 9VC net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1685.45x
ATAI Life Sciences NV's market cap is 1685.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.75 Billion | $20.38 Million | -$167.81 Million | 135.04x | N/A |
| 2022 | $985.16 Million | $233.00K | -$152.38 Million | 4228.14x | N/A |
| 2023 | $588.55 Million | $314.00K | -$40.22 Million | 1874.35x | N/A |
| 2024 | $519.12 Million | $308.00K | -$149.27 Million | 1685.45x | N/A |
Competitor Companies of 9VC by Market Capitalization
Companies near ATAI Life Sciences NV in the global market cap rankings as of November 2, 2026. Also see how large is ATAI Life Sciences NV's balance sheet for a full breakdown of the balance sheet.
Key companies related to ATAI Life Sciences NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of ATAI Life Sciences NV (2021–2025)
Market capitalization of ATAI Life Sciences NV from 2021 to today. Between 2021 and today, ATAI Life Sciences NV's market cap moved from $2.75 Billion to $ 1.45 Billion, with a yearly change of -24.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.45 Billion | +180.25% |
| 2024 | €519.12 Million | -11.80% |
| 2023 | €588.55 Million | -40.26% |
| 2022 | €985.16 Million | -64.20% |
| 2021 | €2.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of ATAI Life Sciences NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Billion USD |
| MoneyControl | $1.27 Billion USD |
| MarketWatch | $1.27 Billion USD |
| marketcap.company | $1.27 Billion USD |
| Reuters | $1.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more